Salbutamol Tolerance Onset
Information source: University of Saskatchewan
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma
Intervention: salbutamol (Drug); Placebo (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: University of Saskatchewan Official(s) and/or principal investigator(s): Donald W Cockcroft, MD, Principal Investigator, Affiliation: University of Saskatchewan
Summary
Overuse of inhaled bronchodilator beta agonist medication results in a loss of effectiveness
(i. e. tolerance). This has been shown for the short acting beta agonist salbutamol and the
long acting beta agonist salmeterol. Tolerance to salmeterol is present within 24 hours.
The onset of tolerance to salbutamol is not known.
Clinical Details
Official title: Salbutamol: Tolerance to Bronchoprotection vs. Methacholine: Time Course of Onset
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science
Primary outcome: Airway responsiveness as a measure of salbutamol bronchoprotectionAirway responsiveness as a measure of salbutamol bronchoprotection Airway responsiveness as a measure of bronchoprotection. The primary outcome is to determine the onset of this tolerance. Airway responsiveness as a measure of salbutamol bronchoprotection
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- male or female
- 18 to 65 years of age
- non smoker
- beta agonist naive for at least 14 days
- baseline FEV1 at least 70% predicted
- no respiratory tract infection or allergen exposure (if atopic) within 4 weeks of
visit 1
Exclusion Criteria:
- poorly controlled asthma
- pregnant or lactating women
Locations and Contacts
University of Saskatchewan, Saskatoon, Saskatchewan S7N 0W8, Canada
Additional Information
Starting date: March 2011
Last updated: July 19, 2012
|